21.80
0.00
(0.00%)
As of 8:01:58 AM GMT+2. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
700,966
700,966
674,978
666,823
541,533
Cost of Revenue
170,428
170,428
184,669
199,295
140,255
Gross Profit
530,538
530,538
490,309
467,528
401,278
Operating Expense
432,964
432,964
402,986
396,601
268,443
Operating Income
97,574
97,574
87,323
70,927
132,835
Net Non Operating Interest Income Expense
3,120
3,120
-8,862
-35,434
-30,854
Other Income Expense
-163,800
-163,800
-16,760
-22,191
-45,577
Pretax Income
-63,106
-63,106
61,701
13,302
56,404
Tax Provision
36,454
36,454
19,746
-2,607
14,424
Net Income Common Stockholders
-99,560
-99,560
41,955
15,909
41,980
Average Dilution Earnings
--
--
4,114
--
--
Diluted NI Available to Com Stockholders
-99,560
-99,560
46,069
15,909
41,980
Basic EPS
-1.96
-2.15
0.91
0.35
0.95
Diluted EPS
-1.98
-2.15
0.89
0.34
0.92
Basic Average Shares
46,310.50
46,245
46,222
45,521
44,262
Diluted Average Shares
51,923.50
46,245
51,979
46,538
45,630
Total Operating Income as Reported
-73,371
-73,371
87,675
60,024
89,924
Total Expenses
603,392
603,392
587,655
595,896
408,698
Net Income from Continuing & Discontinued Operation
-99,560
-99,560
41,955
15,909
41,980
Normalized Income
29,547.33
29,547.33
53,225.32
24,522.37
73,918.66
Interest Income
19,689
19,689
11,444
4,542
896
Interest Expense
13,439
13,439
17,310
35,576
28,996
Net Interest Income
3,120
3,120
-8,862
-35,434
-30,854
EBIT
-49,667
-49,667
79,011
48,878
85,400
EBITDA
29,118
29,118
154,585
140,379
113,948
Reconciled Cost of Revenue
148,931
148,931
166,383
165,082
125,260
Reconciled Depreciation
78,785
78,785
75,574
91,501
28,548
Net Income from Continuing Operation Net Minority Interest
-99,560
-99,560
41,955
15,909
41,980
Total Unusual Items Excluding Goodwill
-163,427
-163,427
-16,574
-10,903
-42,911
Total Unusual Items
-163,427
-163,427
-16,574
-10,903
-42,911
Normalized EBITDA
192,545
192,545
171,159
151,282
156,859
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-34,319.67
-34,319.67
-5,303.68
-2,289.63
-10,972.34
12/31/2021 - 5/16/2011
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
PBV.F Prestige Consumer Healthcare Inc.
72.00
+0.70%
S49.DU Supernus Pharmaceuticals Inc
27.40
-0.72%
PB8.BE Phibro Animal Health Corp
15.60
+1.96%
29A.MU Amphastar Pharmaceuticals Inc
21.25
+0.71%
2DT.F Amneal Pharmaceuticals, Inc.
6.20
+8.77%
PB8.F Phibro Animal Health Corporation
15.60
+1.96%
KABRADG.BO Kabra Drugs Limited
11.08
0.00%
PIG.MU Perrigo Co PLC
21.91
+0.41%
29A.SG Amphastar Pharmaceuticals Inc
20.99
-0.62%
354.MU Collegium Pharmaceutical Inc
23.40
+0.86%